Real-World Outcomes of Ixazomib in the Treatment of Multiple Myeloma from a Single Center in China

被引：0
|
作者：
Sui, Weiwei [1 ,2 ]
An, Gang [3 ]
Deng, Shuhui [4 ,5 ]
Xu, Yan [4 ,5 ]
Hao, Mu [6 ,7 ]
Fu Mingwei [6 ,7 ]
Wang, Tingyu [6 ,7 ]
Yi, Shuhua [4 ,5 ]
Zhao, Yaozhong [8 ,9 ,10 ]
Zou, Dehui [4 ,5 ]
Li, Zengjun [11 ]
Qiu, Lugui [6 ,7 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Lymphoma & Myeloma Ctr, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[8] Chinese Acad Med Sci, Hematol Blood Dis Hosp, Tianji, Tianjing, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[10] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
Real-world; Ixazomib; multiple myeloma;
D O I：
10.1182/blood-2019-126718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5581
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
    Yasutomi, Yusuke
    Ribbands, Amanda
    Luke, Emily
    Mcnamara, Simon
    FUTURE ONCOLOGY, 2025, 21 (06) : 681 - 690
  • [32] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
    Cohen, Yael C.
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe E.
    Chubar, Evgeni
    Horowitz, Nethanel
    Kreiniz, Natalia
    Tadmor, Tamar
    Trestman, Svetlana
    Vitkon, Roy
    Rouvio, Ory
    Shvetz, Olga
    Shaulov, Adir
    Ziv-Baran, Tomer
    Avivi, Irit
    ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1273 - 1281
  • [33] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
    Yael C. Cohen
    Hila Magen
    Noa Lavi
    Moshe E. Gatt
    Evgeni Chubar
    Nethanel Horowitz
    Natalia Kreiniz
    Tamar Tadmor
    Svetlana Trestman
    Roy Vitkon
    Ory Rouvio
    Olga Shvetz
    Adir Shaulov
    Tomer Ziv-Baran
    Irit Avivi
    Annals of Hematology, 2020, 99 : 1273 - 1281
  • [34] Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
    Petrakis, Ioannis
    Kontogiorgis, Christos
    Nena, Evangelia
    Delimpasi, Sosana
    Loutsidi, Natasa E.
    Spanoudakis, Emmanouil
    Intzes, Stergios
    Misidou, Christina
    Symeonidou, Marianthi
    Giannakoulas, Nikolaos
    Constantinidis, Theodoros C.
    Terpos, Evangelos
    CANCERS, 2023, 15 (24)
  • [35] Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States
    Megan S. Rice
    Sarah Naeger
    Erin Singh
    Oncology and Therapy, 2021, 9 : 195 - 212
  • [36] Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States
    Rice, Megan S.
    Naeger, Sarah
    Singh, Erin
    ONCOLOGY AND THERAPY, 2021, 9 (01) : 195 - 212
  • [37] The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
    Agoston Gyula Szabo
    Katrine Fladeland Iversen
    Sören Möller
    Torben Plesner
    Clinical Hematology International, 2019, 1 (4) : 220 - 228
  • [38] Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries
    Abildgaard, Niels
    Anttila, Pekka
    Waage, Anders
    Rubin, Katrine Hass
    Orstavik, Sigurd
    Bent-Ennakhil, Nawal
    Ma, Yuanjun
    Freilich, Jonatan
    Hansson, Markus
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [39] Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome
    Boiten, Henk-Jan
    Buijze, Michiel
    Zweegman, Sonja
    Levin, Mark-David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : E832 - E835
  • [40] Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
    Chari, Ajai
    Richardson, Paul G.
    Romanus, Dorothy
    Dimopoulos, Meletios A.
    Sonneveld, Pieter
    Terpos, Evangelos
    Hajek, Roman
    Raju, Aditya
    Palumbo, Antonio
    Cain, Lauren E.
    Blazer, Marlo
    Huang, Hui
    Farrelly, Eileen
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (04) : 421 - 433
12345